Skip to content
Open access

Biomimetic PD-1-Functionalized Immunostimulatory Nanomedicine Enables STING Activation and Durable Antitumor Immunity in Hepatocellular Carcinoma

Jul 2026 · Nano-Micro Letters · Vol 19 · 0 citations · 39 references
Medicine

TL;DR

A biomimetic nanomedicine that integrates photothermal therapy (PTT), STING pathway activation, and immune checkpoint blockade to treat refractory HCC is developed and offers a promising therapeutic paradigm for photothermal immunotherapy of immune-cold HCC.

Abstract

Clinical cohort analyses identify stimulator of interferon genes (STING) signaling as a key determinant of immune responsiveness in hepatocellular carcinoma (HCC), providing a data-driven rationale for nanomedicine design. A carrier-free coordination nanomedicine co-assembles MSA-2 and indocyanine green to couple photothermal-induced immunogenic cell death with STING activation, while PD-1 membrane camouflage enables ~fivefold tumor accumulation and localized checkpoint blockade. This integrated strategy converts immune-cold HCC into an immune-active state, achieving durable tumor control and systemic immune memory against metastasis. Clinical cohort analyses identify stimulator of interferon genes (STING) signaling as a key determinant of immune responsiveness in hepatocellular carcinoma (HCC), providing a data-driven rationale for nanomedicine design. A carrier-free coordination nanomedicine co-assembles MSA-2 and indocyanine green to couple photothermal-induced immunogenic cell death with STING activation, while PD-1 membrane camouflage enables ~fivefold tumor accumulation and localized checkpoint blockade. This integrated strategy converts immune-cold HCC into an immune-active state, achieving durable tumor control and systemic immune memory against metastasis. Hepatocellular carcinoma (HCC) responds poorly to immune checkpoint blockade, largely because of an immunologically cold tumor microenvironment (TME) characterized by deficient antigen presentation and impaired cytotoxic T cell responses. Analysis of numerous HCC clinical cohorts, including our institutional datasets, reveals that stimulator of interferon genes (STING) pathway activity is positively correlated with patient survival, enhanced antigen presentation capacity, and an immune-activated TME. However, achieving effective and controllable STING activation in immune-cold HCC tumors remains challenging. Here, we develop a biomimetic nanomedicine that integrates photothermal therapy (PTT), STING pathway activation, and immune checkpoint blockade to treat refractory HCC. A coordination nanomedicine MCI-NP is engineered by co-encapsulating the STING agonist MSA-2 and indocyanine green (ICG) via Cu2+-mediated chelation, enabling stabilized PTT-induced immunogenic cell death together with robust STING-driven innate immune activation. Further cloaked with PD-1-overexpressing cell membranes, MCI-NP@mPD-1 achieves an approximately fivefold increase in tumor accumulation compared with uncoated MCI-NP and enables localized PD-1/PD-L1 axis blockade. Following a single treatment, MCI-NP@mPD-1-based photothermal immunotherapy effectively suppresses primary tumor growth and significantly prolongs survival by remodeling the TME toward an immune-active state, while inducing durable systemic immune memory that effectively limited postoperative lung metastasis. Without introducing additional nanocarriers or excipients, MCI-NP@mPD-1 offers a promising therapeutic paradigm for photothermal immunotherapy of immune-cold HCC.

Read PDF

Similar papers

Open access Sep 2026

Thymine-functionalized bPEI nanocomplexes for synergistic STING activation and PD-L1 silencing to potentiate cancer immunotherapy.

In vivo studies of both anti-PD-L1-responsive and resistant tumor models demonstrated that intratumoral delivery of bPEI-Thy/siPD-L1 NCs substantially reduced tumor growth and metastatic spread, induced apoptosis, alleviated immunosuppression, and extended survival.

Li-Qing Chen, Mong-Hsiu Song, Ming-Ji Jin et al. · 0 citations
Open access Aug 2026

A dual-ion/immune checkpoint nanoplatform-activated pyroptosis/cGAS-STING signaling transform iMWA into systemic immunotherapy against HCC recurrence

An ion-based immunomodulatory paradigm integrating ICD, innate immune activation, and immune checkpoint blockade is established, offering a promising nanotherapeutic framework for preventing post-ablation HCC recurrence and enhancing immunotherapy in solid tumors.

Mengqi Zhang, Chao Rong, Hejia Qin et al. · 0 citations
Open access Aug 2026

Photocontrolled nanosystem potentiates photo-chemoimmunotherapy against TNBC by integrating apoptosis/ferroptosis/ pyroptosis and STING activation

A spatiotemporally regulated organelle-targeted nanoplatform, IR820-GEM@MIL101 (IGM), is developed, providing a promising strategy for light-regulated combinatorial immunotherapy against aggressive malignancies.

Pan Zhang, Ming-Lun Liu, Lei Huang et al. · 0 citations
Open access Sep 2026

Nanoconjugate Strategy Integrating Immunogenic Cell Death Induction and Innate Immune Activation for Potent Anti‐Cancer Immunity

A carrier‐free peptide–cyclic dinucleotide (CDN) nanoconjugate (PCN) is developed that co‐activates immunogenic cell death (ICD) in tumors and stimulator of interferon genes (STING) signaling in DCs and broadly reprogrammed the tumor microenvironment toward anti‐tumor immunity.

Teng-Yu He, Alexander M. Cryer, Daniela Simental Lopez et al. · 0 citations
Review Open access Aug 2026

Zinc-based nanoplatforms for cancer immunotherapy achieved through the cyclic GMP-AMP synthase-stimulator of interferon genes pathway: Bridging tumor metabolism and immune activation.

How tumor-responsive Zn²⁺ release, oxidative stress, DNA damage, and metabolic remodeling collectively enhance antitumor immunity is highlighted.

Yi-Zi Wang, Yu-Tao Wang, Cheng Zhang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.